Contact

News

Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

Press Release
Apr 09, 2020
ReAlta Life Sciences Strengthens Board of Directors with Election of Edward Heidt as Chair and Appointments Of Dr. Jonathan Zalevsky And Christine Neikirk
Press Release
Feb 06, 2020
ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy
1 2 3 4